| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/24/2008 | EP2004626A2 Benzimidazolyl-pyridine compounds for inflammation and immune-related uses |
| 12/24/2008 | EP2004625A2 C-met protein kinase inhibitors for the treatment of proliferative disorders |
| 12/24/2008 | EP2004624A1 Novel bi-aryl amines |
| 12/24/2008 | EP2004623A1 Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors |
| 12/24/2008 | EP2004621A2 Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof |
| 12/24/2008 | EP2004619A1 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases |
| 12/24/2008 | EP2004618A1 Telomerase inhibitors |
| 12/24/2008 | EP2004617A2 Ceramide kinase modulation |
| 12/24/2008 | EP2004613A2 Bicyclic benzimidazole compounds and their use as metabotropic glutamate receptor potentiators |
| 12/24/2008 | EP2004612A1 N-phenyl-2-0x0-1,4-diazaspir0 [4.5]dec-3-en-1-yl acetamide derivatives and their use as glycine transporter inhibitors |
| 12/24/2008 | EP2004607A2 New compounds |
| 12/24/2008 | EP2004605A1 Piperidine derivatives useful as serotonin transporter inhibitors and neurokinin-1 receptor antagonists |
| 12/24/2008 | EP2004604A1 Substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators |
| 12/24/2008 | EP2004603A2 Polymorphic and pseudopolymorphic forms of trandolaprilat, pharmaceutical compositions and methods for production and use |
| 12/24/2008 | EP2004602A1 Salts with crth2 antagonist activity |
| 12/24/2008 | EP2004601A1 Novel dipeptidyl peptidase iv inhibitors and processes for their preparation and pharmaceutical compositions containing them |
| 12/24/2008 | EP2004600A1 Iap bir domain binding compounds |
| 12/24/2008 | EP2004597A2 1alpha-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin d compounds with a 1,1-dimethylpropyl side chain |
| 12/24/2008 | EP2004596A2 Compositions useful as inhibitors of voltage-gated sodium channels |
| 12/24/2008 | EP2004593A1 Improved crystalline material |
| 12/24/2008 | EP2004591A1 Cyclopropanes with central nervous system activity |
| 12/24/2008 | EP2004576A1 New method for the manufacture of therapeutic compounds and compositions, compounds and compositions produced therewhith, and their use |
| 12/24/2008 | EP2004297A2 Two pore channels as a therapeutic target to protect against myocardial ischemia and as an adjuvant in cardiac surgery |
| 12/24/2008 | EP2004240A2 Rnai-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions |
| 12/24/2008 | EP2004235A2 Composition for cosmetic or pharmaceutical-dermatological use |
| 12/24/2008 | EP2004234A2 Combination of organic compounds |
| 12/24/2008 | EP2004227A2 Compositions and methods for immunisation using cd1d ligands |
| 12/24/2008 | EP2004223A1 Type 5 and type 8 capsular polysaccharides of superproducing staphylococcus aureus strains |
| 12/24/2008 | EP2004203A2 Formulations of low dose diclofenac and beta-cyclodextrin |
| 12/24/2008 | EP2004202A1 Use of a growth-stimulating protein |
| 12/24/2008 | EP2004201A2 Dietary supplements containing probiotics |
| 12/24/2008 | EP2004200A2 Methods for prevention and treatment of conditions arising from local estrogen deficiency |
| 12/24/2008 | EP2004199A1 Treatment of menopause-associated symptoms |
| 12/24/2008 | EP2004198A2 Method of treating pediatric patients with corticosteroids |
| 12/24/2008 | EP2004197A2 Light activated antiviral materials and devices and methods for decontaminating virus infected environments |
| 12/24/2008 | EP2004196A2 Ocular allergy treatments |
| 12/24/2008 | EP2004195A1 Use of 5h-dibenz/b,f/azepine-5-carboxamide derivatives in the treatment of neuropathic pain and neurological disorders |
| 12/24/2008 | EP2004193A2 Ophthalmic compositions for treating ocular hypertension |
| 12/24/2008 | EP2004192A2 Modified macrophage migration inhibitory factor inhibitors |
| 12/24/2008 | EP2004191A1 Trimetazidine for use in the treatment of fibromyalgia syndrome and related conditions |
| 12/24/2008 | EP2004190A1 Non-codeine opioid analgesic process and formulations |
| 12/24/2008 | EP2004189A2 Thiazolidinedione derivatives as pi3 kinase inhibitors |
| 12/24/2008 | EP2004188A2 Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor |
| 12/24/2008 | EP2004187A1 Dietary supplement for healing or regressing symptoms of gastroesophageal reflux disease, gastritis and ulcers |
| 12/24/2008 | EP2004186A2 Varenicline standards and impurity controls |
| 12/24/2008 | EP2004185A2 Novel heterocyclic diphenyl ethers |
| 12/24/2008 | EP2004184A2 Combinations of therapeutic agents for treating cancer |
| 12/24/2008 | EP2004182A1 Benzimidazoles which have activity at m1 receptor and their uses in medicine |
| 12/24/2008 | EP2004181A2 Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
| 12/24/2008 | EP2004180A2 Use of a kinase inhibitor for the treatment of particular resistant tumors |
| 12/24/2008 | EP2004179A1 Medicament, cosmetic or food product comprising an indol compound, the use thereof and the method of isolation thereof from sauerkraut |
| 12/24/2008 | EP2004178A1 Pharmaceutical combination composition comprising at least one pkc inhibitor and at least one jak3 kinase inhibitor for treating autoimmune disorders |
| 12/24/2008 | EP2004177A2 Nitrofuran compounds for the treatment of cancer and angiogenesis |
| 12/24/2008 | EP2004176A1 USE OF N- ( DIBENZ (b, f) OXEPIN-10-YLMETHYL ) N-METHYL-N- PROP- 2 -YNYLAMINE (OMIGAPIL) FOR THE PROPHYLAXIS AND / OR TREATMENT OF CONGENITAL MUSCULAR DYSTROPHY OR MYOPATHY RESULTING FROM COLLAGEN VI DEFICIENCY |
| 12/24/2008 | EP2004175A2 Anti-cancer activity augmentation compounds and formulations and methods of use thereof |
| 12/24/2008 | EP2004174A2 Naphthalenedione compounds |
| 12/24/2008 | EP2004173A2 Use of aminapthone for the preparation of a medicament for treating arteriophaties |
| 12/24/2008 | EP2004171A2 Treatments using citrulline |
| 12/24/2008 | EP2004170A1 Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor |
| 12/24/2008 | EP2004169A1 Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin |
| 12/24/2008 | EP2004168A1 Stable oral pharmaceutical composition containing thyroid hormone receptor agonists |
| 12/24/2008 | EP2004167A1 Renin inhibitors for the treatment of hypertension |
| 12/24/2008 | EP2004166A2 Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases |
| 12/24/2008 | EP2004165A2 Synergistic combinations of anticancer agents for treating cancer |
| 12/24/2008 | EP2004164A1 Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases |
| 12/24/2008 | EP2004163A2 Combinations comprising mtor inhibitors for treating cancer |
| 12/24/2008 | EP2004162A1 Use of polyamines in the treatment of psoriasis |
| 12/24/2008 | EP2004161A1 Oral composition comprising dha and genistein for enhancing skin properties |
| 12/24/2008 | EP2004160A1 Oral composition with an antiageing effect on the skin |
| 12/24/2008 | EP2004159A1 Autoimmune conditions and nadph oxidase defects |
| 12/24/2008 | EP2004158A2 Use of inhibitors of jun n-terminal kinases to treat glaucoma |
| 12/24/2008 | EP2004157A2 Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto |
| 12/24/2008 | EP2004156A2 Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications |
| 12/24/2008 | EP2004155A1 Inhibitors of protein aggregation |
| 12/24/2008 | EP2004148A2 Pharmaceutical formulations: salts of 8-[{1-(3,5-bis (trifluoromethy1)pheny1)-e thoxy}-methy1]-8-pheny1-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same |
| 12/24/2008 | EP2004147A2 Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive |
| 12/24/2008 | EP2004146A1 A tablet of paracetamol containing an encapsulated flavorant |
| 12/24/2008 | EP2004143A2 Compositions including relatively water insoluble/unwettable drugs and methods for using same |
| 12/24/2008 | EP2004142A2 Enhancing solubility and dissolution rate of poorly soluble drugs |
| 12/24/2008 | EP2004139A1 Compositions, methods, and kits using adenosine and inosine in combination for diagnosis and treatment |
| 12/24/2008 | EP2003991A1 Novel nutraceutical compositions |
| 12/24/2008 | EP2003990A2 Association of oleaginous substance with a mixture of at least two cyclodextrins |
| 12/24/2008 | EP2003971A2 Rnai-mediated inhibition of histamine receptor h1-related conditions |
| 12/24/2008 | EP2003970A2 Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin |
| 12/24/2008 | EP2003966A2 Anthracenedione compounds |
| 12/24/2008 | EP1937651B1 Nnrt inhibitors |
| 12/24/2008 | EP1917267B1 Crystal form of asenapine maleate |
| 12/24/2008 | EP1898876B1 Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical presentations |
| 12/24/2008 | EP1805169B1 Histamine h3 receptor inhibitors, their preparation and therapeutic uses |
| 12/24/2008 | EP1727784B1 Improved process for preparation of gabapentin |
| 12/24/2008 | EP1706095B1 Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
| 12/24/2008 | EP1687314B1 PREPARATION OF 1-AZA-2-OXA-DIBENZO [e,h] AZULENES AND THEIR USE FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS |
| 12/24/2008 | EP1660483B1 8-(1-piperazinyl)-quinoline derivatives and their use in the treatment of cns disorders |
| 12/24/2008 | EP1633756B1 A2a adenosine receptor antagonists |
| 12/24/2008 | EP1631373B1 Micropellets, method for the production thereof, and use thereof |
| 12/24/2008 | EP1627866B1 Carboxylic acid compound and medicine containing the same |
| 12/24/2008 | EP1620425B1 Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists |
| 12/24/2008 | EP1620102B1 3-(1-naphthyl)-2-cyanopropanoic acid derivatives as estrogen receptor ligands |
| 12/24/2008 | EP1603555B1 Halogenated triptolide derivatives as immunomodulators and anticancer agents |
| 12/24/2008 | EP1603550B1 Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino)phenylacetic acid |